BioLife Team – biolife

Why AI Product Development Increasingly Depends on Evidence-Grounded Data

BioLife Team / 2026年7月31日

AI product development is going through a major shift. In the past, many teams focused on whether they could build a functioning model. Increasingly, the more important question is what kind of evidence foundation that model is built on. This is not just a change in language. It reflects a more mature stage of the industry. In healthcare especially, AI development is becoming more dependent on evidence-grounded data—data that is not only large in volume, but also meaningfully connected to clinical questions, real outcomes, validation logic, and future use settings.

Perspectives

When Chinese Device Companies Need U.S. Clinical Data Support

BioLife Team / 2026年7月22日

Not every Chinese device company needs U.S. clinical data support at the very beginning. The real question is not simply whether data is needed. The real question is what the company is trying to achieve, where the evidence gap is, and what problem needs to be solved next. Without that clarity, companies often misjudge both the value and the timing of clinical data support.

Perspectives

Why Real-World Evidence Is Becoming the New Gatekeeper for Health AI

BioLife Team / 2026年6月3日

Conversations about health AI over the past few years have focused heavily on model capability: whether the algorithm is advanced enough, whether performance is strong enough, and whether the product can clear a regulatory path. But as we move deeper into 2026, a more fundamental shift is taking place. For many health AI products, the real differentiator is no longer simply whether the model looks strong. It is whether the product can continuously build and demonstrate real-world evidence. That is increasingly becoming the new gatekeeper.